Recent patents in antifungal agent discovery

Bibliography

• Vicente MF, Basilio A, Cabello A, Pelaez F. Microbial natural products as a source of antifungals. Clin Microbiol Infect 2003;9:15-32
   PubMed Web of Science ®Google Scholar
• Chakrabarti A. Microbiology of systemic fungal infections. J Postgrad Med 2005;51:16-20
   Google Scholar
• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54
   PubMed Web of Science ®Google Scholar
• Zacchino S, Yunes R, Cechinel Filho V, et al. The need for new antifungal drugs: screening for antifungal compounds with a selective mode of action with emphasis on the inhibitors of the fungal cell wall. In: Rai M, Mares D, editors. Plant-Derived Antimycotics: Current Trends and Future Prospects. Haworth Press, New York; 2003. p. 1-48
   Google Scholar
• Ablordeppey S, Fan P, Ablordeppey J, Mardenborough L. Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development. Curr Med Chem 1999;6:1151-95
   PubMed Web of Science ®Google Scholar
• Li D, Calderone R. Antifungal drugs, targets and target discovery. In: San-Blas G, Calderone R, editors. Pathogenic Fungi, Host Interaction and Emerging Strategies for Control. Caister Academic Press, Norfolk; 2004. p. 335-56
   Google Scholar
• Boo TW, O'Reilly B, O'Leary J, Cryan B. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 2005;48:251-9
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45:2845-55
   PubMed Web of Science ®Google Scholar
• Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001;7(S2):1-7
   PubMedGoogle Scholar
• Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462-78
   PubMed Web of Science ®Google Scholar
• Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Investig Drugs 2000;9:1797-813
   PubMed Web of Science ®Google Scholar
• Hossain MA, Ghannoum MA. New developments in chemotherapy for non-invasive fungal infections. Expert Opin Investig Drugs 2001;10:1501-11
   PubMed Web of Science ®Google Scholar
• Ng AWK, Wasan KM, Llopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003;6:67-83
   PubMed Web of Science ®Google Scholar
• Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-86
   PubMed Web of Science ®Google Scholar
• Zotchev SB. Polyene macrolide antibiotics and their applications in human therapy. Curr Med Chem 2003;10:211-23
   PubMed Web of Science ®Google Scholar
• Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Antiinfect Ther 2005;3:167-81
   PubMedGoogle Scholar
• Eth Zurich. Preparation of macrolide amphotericin derivatives as antifungal agents. WO07096137 (2007)
   Google Scholar
• Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995;67:79-100
   PubMed Web of Science ®Google Scholar
• Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14-alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 2001;98:3068-73
   PubMed Web of Science ®Google Scholar
• Adams JL, Metcalf BW. Therapeutic consequences of the inhibition of sterol metabolism. In: Comprehensive Medicinal Chemistry. Hansch C, Sammes PG, Taylor JB, editors. Pergamon Press, Oxford; 1990. p. 333-64
   Google Scholar
• Asai K, Tsuchimori N, Okonogi K, et al. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother 1999;43:1163-9
   PubMed Web of Science ®Google Scholar
• Dawson JH, Sono Ml. Cytochrome P-450 and chloroperoxidase: thiolate-ligated heme enzymes. Spectroscopic determination of their active-site structures and mechanistic implications of thiolate ligation. Chem Rev 1987;87:1255-76
   Web of Science ®Google Scholar
• Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003;11:272-9
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emergine azole antifungal agents. Clin Microbiol Rev 1999;12:40-79
   PubMed Web of Science ®Google Scholar
• Di Santo R. Recent developments in antifungal drug discovery. Ann Rep Med Chem 2006;41:299-315
   Web of Science ®Google Scholar
• Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, Mcclish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999;37:1732-8
   PubMed Web of Science ®Google Scholar
• Takeda Chemical Industry Ltd. Preparation of water-soluble triazolium compounds and their use as antifungal agents. JP00086655 (2000)
   Google Scholar
• Hoffmann-La Roche AG. N-Substituted carbamoyloxyalkyl-azolium derivatives. WO0132652 (2001)
   Google Scholar
• Sankyo Co. Ltd. Pharmaceuticals and antifungal agents containing water-soluble triazoles. JP05263636 (2005)
   Google Scholar
• The Board of Governors for Higher Education State of Rhode Island and Providence Plantations. Preparation of azole monosaccharide as antifungal agents. WO05006860 (2005)
   Google Scholar
• Korea Research Institute of Chemical Technology. Preparation of triazolylmethanol derivatives as antifungal agents. WO05014583 (2005)
   Google Scholar
• Aventis Pharma SA. Novel azole or triazole derivatives, method for preparing same and use thereof as antifungal medicines. WO02090350 (2002)
   Google Scholar
• Aventis Pharma SA. Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides. WO02090354 (2002)
   Google Scholar
• Ranbaxy Lab Ltd. Azole derivatives as antifungal agents. WO03086271 (2003)
   Google Scholar
• Ranbaxy Lab Ltd. Azole compounds as antifungal agents. WO03008391 (2003)
   Google Scholar
• Faming Zhuanli Shenqing Gongkai Shuomingshu. Preparation of piperidinyl triazoleethanols as antifungal agents. CN1557808 (2004)
   Google Scholar
• SSP Co. Ltd. Novel azole derivative having antifungal activity. WO04108684 (2004)
   Google Scholar
• Meiji Seika Kaisha Ltd. Triazole derivatives and antifungal agents containing the same. WO04067537 (2004)
   Google Scholar
• Ranbaxy Lab Ltd. Azole derivatives as antifungal agents. WO04018485 (2004)
   Google Scholar
• Valgus JM. What's new in antifungals? Curr Infect Dis Rep 2003;5:16-21
   PubMedGoogle Scholar
• Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002;132:303-11
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1187-92
   PubMed Web of Science ®Google Scholar
• Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 1994;48:471-97
   PubMed Web of Science ®Google Scholar
• Torres-Rodriguez JM, Carrillo-Muñoz A, Gallach-Bau C, Madrenys N. Susceptibility of Candida species to cilofungin (LY-121019). Mycoses 1989;32:316-8
   PubMed Web of Science ®Google Scholar
• Keating G, Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003;63:2235-63
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Micafungin sodium (FK-463). Drugs Today 2002;38:245-57
   PubMed Web of Science ®Google Scholar
• Arévalo MP, Carrillo-Muñoz A-J, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003;51:163-6
   PubMed Web of Science ®Google Scholar
• Eli Lilly & Co. Ring modified cyclic peptide analogs. WO0011023 (2000)
   Google Scholar
• Eli Lilly & Co. Preparation of cyclic peptide antifungal agents. US6384013 (2002)
   Google Scholar
• Merck & Co. Preparation of cyclohexapeptidyl bisamines as antifungal agents. US6030944 (2000)
   Google Scholar
• Cambas Co. Ltd. Preparation of ring modified cyclic peptide analogs as antifungal agents. WO0011023 (2004)
   Google Scholar
• Adaptive Therapeutics, Inc. Antifungal therapeutic agents. WO04050685 (2004)
   Google Scholar
• Hoffman-La Roche AG. Aerothricin analogs, their preparation and use. WO0005251 (2000)
   Google Scholar
• Basilea Pharmaceutica AG. Novel cyclic compounds. WO0153322 (2001)
   Google Scholar
• Dominguez JM, Martin JJ. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother 1998;42:2279-83
   PubMed Web of Science ®Google Scholar
• Gómez-Lorenzo MG, García-Bustos JF. Ribosomal P-protein stalk function is targeted by sordarin antifungals. J Biol Chem 1998;273:25041-4
   PubMed Web of Science ®Google Scholar
• Kamai Y, Kakuta M, Shibayama T, et al. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice. Antimicrob Agents Chemother 2005;49:52-6
   PubMed Web of Science ®Google Scholar
• Basilio A, Justice M, Harris G, et al. The discovery of moriniafungin, a novel sordarin derivative produced by Morinia pestalozzioides. Bioorg Med Chem 2006;14:560-6
   PubMed Web of Science ®Google Scholar
• Sankyo Co. Ltd. Preparation of oxazepane ring-containing zofimarin derivatives and their use as antifungal agents. JP2003261450 (2003)
   Google Scholar
• Sankyo Co. Ltd. Preparation of zofimarin derivatives and their use as antifungal agents. JP2003089684 (2003)
   Google Scholar
• Bristol-Myers Squibb Co. Novel thio derivatives of sordarin as antifungal agents. WO0222567 (2002)
   Google Scholar
• Glaxo Wellcome SA. Carbocyclic derivatives. WO0134582 (2001)
   Google Scholar
• Glaxo Wellcome SA. Antifungal sordaricin derivatives. WO0134583 (2001)
   Google Scholar
• Kolman A. Activity of epothilones. Curr Opin Investig Drugs 2005;6:616-22
   PubMedGoogle Scholar
• Harbor Branch Oceanographic Institution, Inc. Biologically active neopeltolide compounds. US2004266847 (2004)
   Google Scholar
• Kitasato Institute. Novel macrolide derivatives having effect of potentiating antifungal activity. WO04039823 (2004)
   Google Scholar
• Luzhetskyy A, Pelzer S, Bechthold A. The future of natural products as a source of new antibiotics. Curr Opin Investig Drugs 2007;8:608-13
   PubMed Web of Science ®Google Scholar
• Banyu Pharmaceutical Co. Ltd. Sesterpene derivatives exhibiting antifungal activities. WO0008010 (2000)
   Google Scholar
• Pfizer Pharmaceutical Co. Ltd. Antifungal agents containing terpenoid lactone, and its manufacture with Codiniaea talboti. JP20000086651 (2000)
   Google Scholar
• Toa Gosei Chemical Industry Co. Ltd. Preparation of hydronaphthalenes as antifungal agents and drug intermediates. JP2001026564 (2001)
   Google Scholar
• Mercian Co./Eisai Co. Ltd. Novel polycyclic compounds, their use as antifungal agents, and their manufacture with Fumicola species. JP20010354693 (2001)
   Google Scholar
• Cernáková M, Kostálová D. Antimicrobial activity of berberine a constituent of Mahonia aquifolium. Folia Microbiol 2002; 47:375-8
   PubMed Web of Science ®Google Scholar
• Newtreeindustry Co. Ltd. New derivatives of berberrubine and their salts for antibiotics and antifungal agents. WO03051875 (2003)
   Google Scholar
• Daiichi Seiyaku Co. Ltd. Preparation of tricyclic heterocyclic compounds as antimycotic or antifungal agents. JP2007204458 (2007)
   Google Scholar
• Daiichi Seiyaku Co. Ltd. Preparation of bicyclo heterocyclic compounds as antimycotic or antifungal agents. WO07020936 (2007)
   Google Scholar
• F2G Ltd. Antifungal agents. WO05092304 (2005)
   Google Scholar
• Anadys Pharmaceuticals, Inc. Hydrazone, hydrazine and thiosemicarbazone derivatives as antifungal agents. US6329378 (2001)
   Google Scholar
• Bayer Cropscience SA. Mèdicaments antifongiques à base de derives d'arylamidine. EP1413301 (2004)
   Google Scholar
• Isis Pharmaceuticals, Inc. Novel pyranosyl cytosines: pharmaceutical formulations and methods. WO03066633 (2003)
   Google Scholar
• Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997;35:79-86
   PubMedGoogle Scholar
• Willer T, Valero MC, Tanner W, et al. O-mannosyl glycans: from yeast to novel associations with human disease. Curr Opin Struct Biol 2003;13:621-30
   PubMed Web of Science ®Google Scholar
• Oxford Glycosciences (UK) Ltd. Thiazolidine derivatives and its use as antifungal agent. WO0222612 (2002)
   Google Scholar
• Oxford Glycosciences (UK) Ltd. Thiazolidine antifungal agents. WO03070238 (2003)
   Google Scholar
• Oxford Glycosciences (UK) Ltd. Benzylidene thiazolidinediones and their use as antimycotic agents. WO03070239 (2003)
   Google Scholar
• Johnston SRD. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001;2:18-26
   PubMed Web of Science ®Google Scholar
• Bell IM. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? J Med Chem 2004;47:1869-78
   PubMed Web of Science ®Google Scholar
• Banyu Pharmaceutical Co. Ltd. Inhibitor against geranylgeranyltransferase, I-type protein. JP2000204087 (2000)
   Google Scholar
• Banyu Pharmaceutical Co. Ltd. Type I protein, geranylgeranyltransferase inhibitory compound. JP2000204078 (2000)
   Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993;62:385-427
   PubMed Web of Science ®Google Scholar
• Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996;40:2835-41
   PubMed Web of Science ®Google Scholar
• Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995;39:1696-9
   PubMed Web of Science ®Google Scholar
• Essential Therapeutics, Inc. Fungal efflux pump inhibitors. US2003229097 (2003)
   Google Scholar
• Essential Therapeutics, Inc. Fungal efflux pump inhibitors. US6596723 (2003)
   Google Scholar